Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury

Biomaterials

Volumn 31, Issue 30, 2010, Pages 7631-7639

  Baumann, M Douglas ^a,b,c   Kang, Catherine E ^a,b,c   Tator, Charles H ^c   Shoichet, Molly S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drug delivery; Hyaluronan; Hydrogel; Methylcellulose; Nanoparticles; Spinal cord injury

Indexed keywords

BIOPOLYMER MATRIX; CAVITY VOLUME; COMPOSITE HYDROGELS; DATA SUPPORT; DESIGN CRITERION; FURTHER DEVELOPMENT; HYALURONAN; IN-VITRO; IN-VIVO; INJURED SPINAL CORDS; INTRATHECAL; LOCAL DELIVERY; LOCAL DRUG DELIVERY; LOCOMOTOR FUNCTION; METHYLCELLULOSE; MINIMALLY INVASIVE; PLGA NANOPARTICLES; POLY-LACTIDE-CO-GLYCOLIDE; POLYMERIC NANOCOMPOSITES; SIDE EFFECT; SPINAL CORD INJURY; SPINAL CORDS; SUSTAINED RELEASE;

ANIMALS; BIOCOMPATIBILITY; BIOMOLECULES; BLOOD; CONTROLLED DRUG DELIVERY; DOSIMETRY; NANOCOMPOSITES; NANOPARTICLES; PATIENT REHABILITATION;

HYDROGELS;

BIOPOLYMER; GLIAL FIBRILLARY ACIDIC PROTEIN; HYALURONAN METHYLCELLULOSE; HYALURONAN METHYLCELLULOSE POLYGLACTIN; HYALURONIC ACID; METHYLCELLULOSE; METHYLCELLULOSE POLYGLACTIN; NANOCOMPOSITE; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HYDROGEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MINIMALLY INVASIVE PROCEDURE; MOTOR PERFORMANCE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SPINAL CORD INJURY; SUSTAINED DRUG RELEASE;

ANIMALS; BEHAVIOR, ANIMAL; BIOCOMPATIBLE MATERIALS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; FEMALE; HUMANS; HYALURONIC ACID; HYDROGELS; INJECTIONS, SPINAL; LACTIC ACID; MATERIALS TESTING; METHYLCELLULOSE; MOTOR ACTIVITY; NANOCOMPOSITES; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD INJURIES;

ANIMALIA; RATTUS;

EID: 77955769763     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.07.004     Document Type: Article

References (59)

1. Tator C.H. Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. J Spinal Cord Med 1996, 19(4):206-214.
2. Girard C., Bemelmans A.P., Dufour N., Mallet J., Bachelin C., Nait-Oumesmar B., et al. Grafts of brain-derived neurotrophic factor and neurotrophin 3-transduced primate Schwann cells lead to functional recovery of the demyelinated mouse spinal cord. J Neurosci 2005, 25(35):7924-7933.
3. Rabchevsky A.G., Fugaccia I., Fletcher-Turner A., Blades D.A., Mattson M.P., Scheff S.W. Basic fibroblast growth factor (bFGF) enhances tissue sparing and functional recovery following moderate spinal cord injury. J Neurotrauma 1999, 16(9):817-830.
4. Schwab M.E. Nogo and axon regeneration. Curr Opin Neurobiol 2004, 14(1):118-124.
5. Fitch M.T., Doller C., Combs C.K., Landreth G.E., Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 1999, 19(19):8182-8198.
6. Stroncek J.D., Reichert W.M. Overview of wound healing in different tissue types. Indwelling neural implants: strategies for contending with the in vivo environment 2008, CRC Press, Boca Raton. W. Reichert (Ed.).
7. Ramer L.M., Ramer M.S., Steeves J.D. Setting the stage for functional repair of spinal cord injuries: a cast of thousands. Spinal Cord 2005, 43(3):134-161.
8. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008, 209(2):378-388.
9. Bradbury E.J., Khemani S., Von R., King, Priestley J.V., McMahon S.B. NT-3 promotes growth of lesioned adult rat sensory axons ascending in the dorsal columns of the spinal cord. Eur J Neurosci 1999, 11(11):3873-3883.
10. Tuszynski M.H., Grill R., Jones L.L., Brant A., Blesch A., Low K., et al. NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection. Exp Neurol 2003, 181(1):47-56.
11. Tobias C.A., Shumsky J.S., Shibata M., Tuszynski M.H., Fischer I., Tessler A., et al. Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured spinal cord stimulates sprouting, partially rescues axotomized red nucleus neurons from loss and atrophy, and provides limited regeneration. Exp Neurol 2003, 184(1):97-113.
12. Zahir T., Chen Y.F., MacDonald J.F., Leipzig N., Tator C.H., Shoichet M.S. Neural stem/progenitor cells differentiate in vitro to neurons by the combined action of dibutyryl cAMP and interferon-gamma. Stem Cells Dev 2009, 18(10):1423-1432.
13. Hawryluk G., Karmimi-Abdolrezaee S., Eftekharpour E., Fehlings M. Examination of the early effects of neural precursor cell transplantation on the peri-lesional environment of the injured spinal cord. J Neurotrauma 2008, 25(7):P296.
14. Chvatal S.A., Kim Y.T., Bratt-Leal A.M., Lee H., Bellamkonda R.V. Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 2008, 29(12):1967-1975.
15. Jain A., Kim Y.T., McKeon R.J., Bellamkonda R.V. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006, 27(3):497-504.
16. Wang Y.C., Wu Y.T., Huang H.Y., Lin H.I., Lo L.W., Tzeng S.F., et al. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 2008, 29(34):4546-4553.
17. Tator C.H. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 2006, 59(5):957-982. discussion: 982-7.
18. Straley K.S., Foo C.W., Heilshorn S.C. Biomaterial design strategies for the treatment of spinal cord injuries. J Neurotrauma 2010, 27(1):1-19.
19. Gupta D., Tator C.H., Shoichet M.S. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006, 27(11):2370-2379.
20. Jimenez Hamann M.C., Tsai E.C., Tator C.H., Shoichet M.S. Novel intrathecal delivery system for treatment of spinal cord injury. Exp Neurol 2003, 182(2):300-309.
21. Ballios B.G., Cooke M.J., van der Kooy D., Shoichet M.S. A hydrogel-based stem cell delivery system to treat retinal degenerative diseases. Biomaterials 2010, 31(9):2555-2564.
22. Jimenez Hamann M.C., Tator C.H., Shoichet M.S. Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp Neurol 2005, 194(1):106-119.
23. Kang C.E., Poon P.C., Tator C.H., Shoichet M.S. A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair. Tissue Eng Part A 2009, 15(3):595-604.
24. Norenberg M.D., Smith J., Marcillo A. The pathology of human spinal cord injury: Defining the problems. J Neurotrauma 2004, 21(4):429-440.
25. Fehlings M.G., Perrin R.G. The timing of surgical intervention in the treatment of spinal cord injury: a systematic review of recent clinical evidence. Spine 2006, 31(11 Suppl.):S28-S35. discussion: S36.
26. Baumann M.D., Kang C.E., Stanwick J.C., Wang Y., Kim H., Lapitsky Y., et al. An injectable drug delivery platform for sustained combination therapy. J Control Release 2009, 138(3):205-213.
27. Wong D.Y., Hollister S.J., Krebsbach P.H., Nosrat C. Poly(epsilon-caprolactone) and poly (L-lactic-co-glycolic acid) degradable polymer sponges attenuate astrocyte response and lesion growth in acute traumatic brain injury. Tissue Eng 2007, 13(10):2515-2523.
28. Fournier E., Passirani C., Montero-Menei C.N., Benoit J.P. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003, 24(19):3311-3331.
29. Kou J.H., Emmett C., Shen P., Aswani S., Iwamoto T., Vaghefi F., et al. Bioerosion and biocompatibility of poly(d, l-lactic-co-glycolic acid) implants in brain. J Control Release 1997, 43(2-3):123-130.
30. Lemons M.L., Howland D.R., Anderson D.K. Chondroitin sulfate proteoglycan immunoreactivity increases following spinal cord injury and transplantation. Exp Neurol 1999, 160(1):51-65.
31. Sarkar N. Kinetics of thermal gelation of methylcellulose and hydroxypropylmethylcellulose in aqueous-solutions. Carbohydr Polym 1995, 26(3):195-203.
32. Zheng P.J., Li L., Hu X., Zhao X.Y. Sol-gel transition of methylcellulose in phosphate buffer saline solutions. J Poly Sci B Polym Phys 2004, 42(10):1849-1860.
33. Tate M.C., Shear D.A., Hoffman S.W., Stein D.G., LaPlaca M.C. Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 2001, 22(10):1113-1123.
34. Kang C.E., Tator C.H., Shoichet M.S. Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system. J Control Release 2010, 144(1):25-31.
35. Topsakal C., Akpolat N., Erol F.S., Ozveren M.F., Akdemir I., Kaplan M., et al. Seprafilm superior to Gore-Tex in the prevention of peridural fibrosis. J Neurosurg 2004, 101(2):295-302.
36. Kato T., Haro H., Komori H., Shinomiya K. Evaluation of hyaluronic acid sheet for the prevention of postlaminectomy adhesions. Spine J 2005, 5(5):479-488.
37. Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007, 23:435-461.
38. Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28(1):5-24.
39. Kohane D.S., Tse J.Y., Yeo Y., Padera R., Shubina M., Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res A 2006, 77(2):351-361.
40. Domnina Y.A., Yeo Y., Tse J.Y., Bellas E., Kohane D.S. Spray-dried lipid-hyaluronan-polymethacrylate microparticles for drug delivery in the peritoneum. J Biomed Mater Res A 2008, 87(3):825-831.
41. Soderquist R.G., Sloane E.M., Loram L.C., Harrison J.A., Dengler E.C., Johnson S.M., et al. Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res 2010, 27(5):841-854.
42. Rivlin A.S., Tator C.H. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 1978, 10(1):38-43.
43. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12(1):1-21.
44. Schupper N., Rabin Y., Rosenbluh M. Multiple stages in the aging of a physical polymer gel. Macromolecules 2008, 41(11):3983-3994.
45. Schexnailder P., Schmidt G. Nanocomposite polymer hydrogels. Colloid Polym Sci 2009, 287(1):1-11.
46. Poon P.C., Gupta D., Shoichet M.S., Tator C.H. Clip compression model is useful for thoracic spinal cord injuries: histologic and functional correlates. Spine 2007, 32(25):2853-2859.
47. Kobayashi Y., Okamoto A., Nishinari K. Viscoelasticity of hyaluronic acid with different molecular weights. Biorheology 1994, 31(3):235-244.
48. Fehlings M.G. The impact of continued cord compression following traumatic spinal cord injury. J Neurosurg Spine 2009, 11(5):568-569.
49. Nowak D.D., Lee J.K., Gelb D.E., Poelstra K.A., Ludwig S.C. Central cord syndrome. J Am Acad Orthop Surg 2009, 17(12):756-765.
50. Athanasiou K.A., Niederauer G.G., Agrawal C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid polyglycolic acid copolymers. Biomaterials 1996, 17(2):93-102.
51. Janmey P.A., Winer J.P., Murray M.E., Wen Q. The hard life of soft cells. Cell Motil Cytoskeleton 2009, 66(8):597-605.
52. Wheeler J.C., Woods J.A., Cox M.J., Cantrell R.W., Watkins F.H., Edlich R.F. Evolution of hydrogel polymers as contact lenses, surface coatings, dressings, and drug delivery systems. J Long Term Eff Med Implants 1996, 6(3-4):207-217.
53. Preul M.C., Bichard W.D., Muench T.R., Spetzler R.F. Toward optimal tissue sealants for neurosurgery: use of a novel hydrogel sealant in a canine durotomy repair model. Neurosurgery 2003, 53(5):1189-1198.
54. Haq I., Cruz-Almeida Y., Siqueira E.B., Norenberg M., Green B.A., Levi A.D. Postoperative fibrosis after surgical treatment of the porcine spinal cord: a comparison of dural substitutes. J Neurosurg Spine 2005, 2(1):50-54.
55. Yeo Y., Ito T., Bellas E., Highley C.B., Marini R., Kohane D.S. In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. Ann Surg 2007, 245(5):819-824.
56. Fawcett J.W. Overcoming inhibition in the damaged spinal cord. J Neurotrauma 2006, 23(3-4):371-383.
57. Rhodes K.E., Fawcett J.W. Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?. J Anat 2004, 204(1):33-48.
58. Jones L.L., Tuszynski M.H. Chronic intrathecal infusions after spinal cord injury cause scarring and compression. Microsc Res Tech 2001, 54(5):317-324.
59. McCall T.D., MacDonald J.D. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery 2006, 59(3):634-640. discussion: 634-40.